U.S. flag

An official website of the United States government

GTR Home > Tests > Comprehensive breast and ovarian cancer panel testing (18 genes)

Laboratory contact

Laboratory information

Help

Molecular Genetics Laboratory
North York General Hospital

Laboratory director(s)

Help
  • Hong Wang, PhD, ABMG, FACMG, DABMG, Lab Director

Laboratory contact

Help
  • Genetics Program
  • Toronto, Ontario M2K 1E1
  • Canada

Laboratory services offered

Help
  • Clinical Testing/Confirmation of Mutations Identified Previously
  • Custom Sequence Analysis
  • Custom microarray analysis
  • Identity Testing
  • Maternal cell contamination study (MCC)
  • Uniparental Disomy (UPD) Testing

Laboratory credentials

Certifications

Help
  • Ministry of Health Long Term Care (MOHLTC), Number: 4047, Expiration: 2021-04-13
  • Institute for Quality Management in Healthcare (Laboratory Accre, Number: 4047/0128, Expiration: 2023-06-08

Suggested reading

  • USPSTF, 2019
    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA1/2-Related Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force
  • USPSTF, 2013
    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation (See 2019 Update)
  • Phillips et al., 2013
    Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.
  • Domchek et al., 2010
    Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers with Cancer Risk and Mortality
  • NCI PDQ, Cancer Genetics Counseling
    Cancer Genetics Risk Assessment and Counseling (PDQ®): Health Professional Version

Practice guidelines

  • NCCN, 2022
    NCCN Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic version 2.2022
  • NICE, 2019
    UK NICE Clinical Guideline CG164, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2019
  • ACMG ACT, 2019
    American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, BRCA1 and BRCA2 Pathogenic Variants (Hereditary Breast and Ovarian Cancer), 2019

Consumer resources

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.